Last Updated: September 25, 2026

Litigation Details for DISH Technologies L.L.C. v. lululemon athletica inc. (D. Del. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in DISH Technologies L.L.C. v. lululemon athletica inc.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

DISH Technologies v. lululemon Patent Litigation: Case No. 1:21-cv-00532

Last updated: September 25, 2026

DISH Technologies L.L.C. sued lululemon athletica inc. in the U.S. District Court for the District of Delaware over technology used in lululemon’s MIRROR connected-fitness platform. The case was a patent-infringement dispute involving streaming, delivery, and interactive presentation of video content rather than a pharmaceutical or biologic product. Orange Book listings, FDA exclusivity, Paragraph IV certifications, biosimilar substitution and Hatch-Waxman litigation are not applicable.

What is DISH Technologies v. lululemon athletica?

The case is a patent-infringement action filed by DISH Technologies against lululemon in 2021. The asserted technology concerned delivery and presentation of audiovisual programming through internet-connected consumer devices, including the MIRROR fitness system.

Item Case information
Plaintiff DISH Technologies L.L.C.
Defendant lululemon athletica inc.
Court U.S. District Court for the District of Delaware
Case number 1:21-cv-00532
Filing year 2021
Technology at issue Streaming and interactive delivery of audiovisual content
Accused product lululemon MIRROR platform and related services
Legal theory Patent infringement under 35 U.S.C. § 271
Regulatory pathway No FDA approval pathway
Orange Book status Not applicable
Biosimilar risk Not applicable

DISH Technologies is a DISH Network affiliate that has pursued patent litigation against companies operating streaming-video services and connected-content platforms. Lululemon became a target after its acquisition of MIRROR, an interactive home-fitness business that delivered instructor-led classes through a connected display and software platform.

What patents and technology were at issue?

The dispute focused on the technical operation of a connected-video service. The asserted claims reportedly covered functions associated with selecting, distributing, receiving and presenting video content through a networked system.

The relevant technology categories included:

  • Delivery of audiovisual programming over a communications network.
  • Streaming or transmission of content to a user device.
  • Selection and presentation of programming.
  • Interactive control of video content.
  • Use of connected hardware and software to deliver instructor-led programming.
  • Integration of content services with a consumer-facing device.

The infringement analysis would have depended on the specific claim language, accused MIRROR architecture and source of the video stream. A platform can infringe a patent even when the end-user device is not itself the entire accused system. Claims directed to coordinated operation among servers, software and playback devices can create direct-infringement exposure based on the operator’s control of the service.

Public case summaries identify the action as a DISH patent case involving lululemon’s MIRROR business. The operative complaint and docket filings should control the definitive list of asserted patents, claim charts and infringement theories. The case identifier alone does not establish that every DISH streaming patent was asserted against lululemon.

When was the lawsuit filed?

DISH filed the action in the District of Delaware in 2021. The case number is 1:21-cv-00532.

The selection of Delaware was commercially significant. Lululemon is incorporated in Delaware, making the forum available under general corporate-jurisdiction principles. Delaware also has extensive experience handling complex patent litigation involving software, streaming platforms and connected devices.

The case was assigned to the District of Delaware’s patent docket, where the parties would ordinarily proceed through:

  1. Pleadings and infringement contentions.
  2. Exchange of technical information and source-code discovery.
  3. Claim-construction briefing under the district’s patent procedures.
  4. Expert discovery.
  5. Summary-judgment motions.
  6. Trial or negotiated resolution.

What was lululemon’s likely defense strategy?

Lululemon’s defenses would have included noninfringement, invalidity and limits on the scope of the asserted claims.

Noninfringement

The central noninfringement issue would have been whether MIRROR’s architecture practiced every limitation of each asserted claim. For system claims, DISH would have needed to connect the claim elements to the actual operation of the MIRROR service, including the role of lululemon-controlled servers, applications and connected displays.

Potential factual disputes included:

  • Whether MIRROR transmitted content in the manner required by the claims.
  • Whether lululemon controlled all elements of an accused system.
  • Whether content was streamed, downloaded or delivered through a hybrid architecture.
  • Whether user interaction satisfied claimed selection or control functions.
  • Whether third-party technology providers performed relevant claim steps.

Invalidity

Lululemon could challenge validity under several provisions of the Patent Act, including:

  • Anticipation under 35 U.S.C. § 102.
  • Obviousness under 35 U.S.C. § 103.
  • Lack of written description or enablement under § 112.
  • Indefiniteness under § 112(b).
  • Patent-eligibility challenges under § 101 for claims directed to abstract content-delivery concepts.

Streaming patents often face prior-art challenges based on earlier cable, satellite, internet-video and digital-video-recorder systems. The practical strength of DISH’s case would have depended on whether the asserted claims required a specific technical arrangement rather than merely the business concept of providing exercise videos over the internet.

How strong was DISH’s patent position?

DISH’s position had potential leverage because connected-fitness services combine hardware, software, content delivery and user interaction. That combination can create several infringement theories against a platform operator.

The estate’s strength would depend on four factors:

Factor Relevance to DISH’s case
Claim specificity Narrow technical claims are harder to read on MIRROR but may be more defensible against invalidity attacks.
Patent age Older priority dates can support prior-art challenges but may create earlier effective dates against later products.
System control Claims requiring multiple actors create divided-infringement risks.
Technical proof Source-code and network-architecture evidence would determine whether MIRROR practiced each limitation.

DISH’s broader litigation program also increased settlement leverage. A defendant facing patents asserted against multiple streaming services may prefer a commercial resolution rather than fund a full invalidity record that could affect other disputes.

The principal weakness would have been the possibility that MIRROR used a materially different architecture from the systems described in the asserted patents. A general similarity between streaming fitness classes and television or video-on-demand services does not establish infringement.

Did the case involve Paragraph IV challenges or FDA exclusivity?

No. The case was not a pharmaceutical patent action.

Paragraph IV certifications apply to abbreviated new drug applications under the Hatch-Waxman Act. The Orange Book identifies patents associated with approved drug products. MIRROR is a connected-fitness platform, not an FDA-approved drug, biologic or medical product at issue in this litigation.

Accordingly:

  • There was no Paragraph IV notice letter.
  • There was no 30-month Hatch-Waxman stay.
  • There was no FDA regulatory exclusivity period.
  • There was no biosimilar applicant.
  • There was no Orange Book patent listing relevant to the dispute.
  • Generic-launch analysis does not apply.

What litigation risks did lululemon face?

Lululemon faced several categories of exposure if DISH prevailed.

Injunctive relief

DISH could seek an injunction against continued use of an infringing MIRROR system. After eBay Inc. v. MercExchange, L.L.C., permanent injunctions require proof of the traditional equitable factors. Patent owners often seek an injunction but may instead obtain a running royalty or lump-sum license.

An injunction would have created operational risk if the accused functions were embedded in MIRROR’s core software or content-delivery infrastructure. A workaround would have required software changes, server modifications or a redesign of the user experience.

Monetary damages

DISH could seek at least a reasonable royalty. Depending on the infringement period and the evidence, damages could have been based on:

  • A royalty on MIRROR hardware sales.
  • A royalty on subscriptions.
  • A royalty on the accused portion of the platform.
  • A lump-sum payment for past use.
  • Enhanced damages for willful infringement if the statutory standard was met.

The financial exposure was likely tied to MIRROR revenue and subscriber activity rather than lululemon’s entire apparel business. That distinction limited the direct damages base but did not eliminate strategic risk.

Business disruption

MIRROR was integrated into lululemon’s digital-fitness strategy. Patent claims reaching content delivery or core platform functions could have affected:

  • New device sales.
  • Existing subscriber services.
  • Software updates.
  • Content distribution.
  • Partnerships with instructors and studios.
  • Future connected-fitness products.

How did the dispute affect lululemon’s commercial position?

The litigation formed part of the legal risk surrounding lululemon’s acquisition and operation of MIRROR. Lululemon acquired MIRROR in 2020 for approximately $500 million, before the DISH complaint was filed. The lawsuit therefore presented a post-acquisition technology risk tied to an asset that had already required substantial capital investment.

The commercial exposure was greater than the damages associated with a single patent claim if the litigation threatened the viability of the MIRROR platform. A settlement could preserve service continuity while allowing lululemon to limit discovery costs, injunction risk and future product restrictions.

The dispute also had implications for valuation of connected-fitness intellectual property. Platform operators must assess not only patents covering the device, but also patents covering:

  • Cloud delivery.
  • Content authorization.
  • Playback controls.
  • User authentication.
  • Subscription management.
  • Interactive overlays.
  • Remote instruction.
  • Data synchronization.

What is the current litigation status?

The case should be evaluated by reference to the operative District of Delaware docket, including any amended pleadings, claim-construction orders, dispositive rulings, stipulations and final judgment. The case number identifies the action but does not by itself establish the status of individual patent claims or the existence of a license.

No FDA, Orange Book or biosimilar event is associated with the matter. Any resolution would be a technology-patent disposition, such as dismissal, settlement, license, judgment or post-trial order.

How does this case compare with pharmaceutical patent litigation?

Issue DISH Technologies v. lululemon Pharmaceutical patent case
Product Connected-fitness platform Drug or biologic
Regulator No FDA approval issue in the patent dispute FDA approval is central
Patent listing No Orange Book listing Orange Book or biologic patent disclosure may apply
Generic or biosimilar entry Not applicable Core commercial issue
Main technical evidence Software, network architecture and source code Chemistry, formulation, clinical and manufacturing evidence
Damages base Device, subscription or platform revenue Drug sales and launch timing
Injunction risk Service redesign or platform restriction Delayed generic or biosimilar launch
Commercial resolution License, redesign or dismissal Settlement with entry date and patent terms

Key Takeaways

  • DISH Technologies sued lululemon in the District of Delaware in Case No. 1:21-cv-00532.
  • The dispute concerned patent rights implicated by lululemon’s MIRROR connected-fitness platform.
  • The technical issues centered on streaming, network delivery, playback and interactive video functions.
  • The case was not a pharmaceutical action and involved no Orange Book listing, Paragraph IV certification, FDA exclusivity or biosimilar risk.
  • Lululemon’s principal defenses would have been noninfringement and invalidity.
  • The commercial risk extended beyond damages because an injunction could have required changes to MIRROR’s software or service architecture.
  • The definitive patent list, claim status and disposition must be taken from the operative pleadings and final District of Delaware docket entries.

FAQs

Was lululemon accused of infringing DISH television patents?

Yes. The dispute involved DISH patent rights directed to technologies used to deliver and present audiovisual content through connected systems. The accused MIRROR platform delivered instructor-led video programming through connected hardware and software.

Did the DISH lawsuit threaten lululemon’s apparel business?

No direct infringement theory targeted lululemon’s apparel products. The commercial risk was concentrated in the MIRROR connected-fitness business, including its hardware, software and subscription services.

Could DISH have obtained an injunction against MIRROR?

DISH could seek injunctive relief, but an injunction would require satisfaction of the equitable factors established by the Supreme Court. The practical result could have been a license, software redesign or restriction of affected functions rather than a complete shutdown.

Did the case involve a drug patent expiration date?

No. The patents at issue were technology patents. Drug exclusivity and pharmaceutical patent-expiration analysis do not apply.

What evidence would be most important in the case?

The most important evidence would include the asserted claim language, MIRROR source code, system architecture, network diagrams, technical documentation, third-party agreements, expert reports and prior-art references. Those materials would determine both infringement and validity.

References

  1. DISH Technologies L.L.C. v. lululemon athletica inc., No. 1:21-cv-00532, U.S. District Court for the District of Delaware, docket and pleadings.

  2. U.S. Patent Act, 35 U.S.C. §§ 101-103, 112, 271, 281 and 284.

  3. eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006).

  4. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

  5. U.S. Patent and Trademark Office. (n.d.). Patent Trial and Appeal Board and patent litigation resources. U.S. Department of Commerce.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.